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HypertensionCLC-K chloride channels play a crucial role in kidney physiology and genetic mutations, affecting their function are
responsible for severe renal salt loss in humans. Thus, compounds that selectively bind to CLC-Ka and/or CLC-Kb
channels and modulate their activity may have a signiﬁcant therapeutic potential. Here, we compare the biophys-
ical and pharmacological behaviors of human CLC-K channels expressed either in HEK293 cells or in Xenopus oo-
cytes and we show that CLC-K channel properties are greatly inﬂuenced by the biochemical environment
surrounding the channels. Indeed, in HEK293 cells the potentiating effect of niﬂumic acid (NFA) on CLC-Ka/
barttin and CLC-Kb/barttin channels seems to be absentwhile the blocking efﬁcacy of niﬂumic acid and benzofuran
derivatives observed in oocytes is preserved. The NFA block does not seem to involve the accessory subunit barttin
on CLC-K1 channels. In addition, the sensitivity of CLC-Ks to external Ca2+ is reduced in HEK293 cells. Based on our
ﬁndings, we propose that mammalian cell lines are a suitable expression system for the pharmacological proﬁling
of CLC-Ks.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Human kidney CLC-Ka and CLC-Kb chloride channels (and their rat
orthologs CLC-K1 and CLC-K2) are located in Henle's loop, in the distal
convoluted tubule and in the cortical collecting duct of the nephron
where they govern chloride (Cl−) absorption and urine concentration
[1]. In humans, loss-of-function mutations of the genes encoding CLC-
Kb (CLCNKB) and the barttin regulatory subunit are responsible for the
recessive Bartter syndrome, characterized by urinary salt loss [2,3]. Fur-
thermore, CLCNKA and CLCNKB gain-of-function polymorphisms have
been proposed to be associated with salt sensitive hypertension [4,5].
Thus, the identiﬁcation of selective CLC-K ligands that can be potentially
used in therapy is highly desirable. In parallel, the need of a suitable ex-
pression system for a detailed biophysical and pharmacological charac-
terization of human CLC-K channels has proven to be essential to
translate in vitro pharmacological results to the in vivo context.
During the past years, different cellular systems have been tested in
order to characterize CLC-K currents. So far, the only data regarding na-
tive CLC-K currents have been obtained from rodent renal tubules re-
cordings [6-8] which are highly relevant because preclinical drugbryonic kidney; MDCK, Madin
T, distal convoluted tubule
39 080 5442801.screening is mostly performed in these animal models. However, as
the precisemolecular identity of native rodent channels remains elusive
i.e. it is unknown if they are mediated by CLC-K1, CLC-K2 or by
heteromers of these, a precise comparison with recombinant human
channels is still not possible [9]. Furthermore, mouse CLC-K1 and
human CLC-Ka might not necessarily behave similarly.
Therefore, most of the information on the pharmacological proper-
ties of human CLC-K channels comes from in vitro studies performed
in Xenopus oocytes. For instance, this cellular system allowed to assess
that CLC-Ka and CLC-Kb channels require the barttin subunit to become
anion conducting [10], whereas rodent CLC-K1 channels show function-
al expression even in the absence of barttin [11,12]. Moreover, in
Xenopus oocytes CLC-K/barttin channels are alsomodulated bymultiple
signaling cascades, such as the Ser/Thr serum- and glucocorticoid-
dependent protein kinases [13]. Remarkably, the expression of human
CLC-K channels in Xenopus oocytes allowed the rapid screening of
novel molecules acting as openers or inhibitors [14,15]. In this frame-
work, we recently discovered that phenyl-benzofuran carboxylic acid
derivatives are the most potent CLC-Ka and CLC-Kb inhibitors so far de-
scribed [15], whereas niﬂumic acid (NFA) is themost effective activator
of human CLC-K channels [14,16]. These data suggested the presence of
two distinct binding sites, an activating site and a blocking site [16].
However, when CLC-K channels have been expressed inmammalian
cells, several functional differences have been observed. Indeed, while
CLC-K channels showed clear voltage-dependent gating in Xenopus oo-
cytes, their current kinetics were less pronounced in mammalian cells
[9,10,12,15,17–21]. The reasons for this difference are not clear. In
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mammalian cell lines is unknown.
Here we provide, for the ﬁrst time, a pharmacological characteriza-
tion of CLC-K channels expressed in HEK293 cells. We investigate
human CLC-Ka and CLC-Kb as well as rodent CLC-K1 expressed with
and without barttin and record their response to blockers and activa-
tors, to extracellular pH, Ca2+, kinases and membrane ﬂuidity. By
performing a parallel analysis in mammalian cells and Xenopus oocytes,
we obtained a comprehensive picture of CLC-K channel properties
based on the distinct expression system. Our results validate mammali-
an cell lines as a suitable expression system to test novel chemical com-
pounds targeting human CLC-Ks.
2. Materials and methods
2.1. Electrophysiology
Expression and electrophysiological measurements in oocytes were
performed as previously described [14].WT CLC-Ka, CLC-Kb and CLC-K1
RNAs were co-expressed in Xenopus oocytes with the human Y98A
barttin in a 1:1 weight ratio (~5 ng each). Currents were recorded in
the standard solution containing (in mM) 90 NaCl, 10 CaCl2, 1 MgCl2,
and 10 HEPES at pH 7.3. Similar voltage-clamp pulse protocols for
CLC-Ka and CLC-Kb, with a longer pulse duration for CLC-Kb, were
used: from a holding potential of−30 mV, after a prepulse to 60 mV
(or−100 mV) for 100 or 200 ms (for CLC-Ka and CLC-Kb respectively),
voltage was stepped from−140 to 80 mV in 20mV increments for 200
or 500 ms (for CLC-Ka and CLC-Kb respectively), followed by a ﬁnal tail
pulse to−100mV(or+60mV). To evaluate the on-set andwash-out of
drug effects a pulse to 60 mV was applied every 2 s. The half maximal
inhibitory concentrations for drugs showing blocking activity, IC50,
were determined by calculating the ratio of the steady-state current
with and without the drug and ﬁtting the ratios to the equation: I(c) /
I(0)=1 / (1+c / IC50)where c is the concentration. For drugs showing
an IC50 N 1mM,we did not determine the accurate IC50 value because it
would require large amounts of drug, and it falls outside of the aims of
this study. Methyl-beta-cyclodextrin (Sigma Aldrich, St. Louis, MO)
and ﬂuvastatin (Sigma Aldrich, St. Louis, MO) were dissolved in the oo-
cyte maintenance solution containing (in mM): 90 NaCl, 2 KCl, 1 MgCl2,
1 CaCl2, 10 HEPES at pH 7.5. To evaluate the effect of ﬂuvastatin on CLC-
Ka in Xenopus oocytes, currents were measured for a large number of
oocytes (resulting in I0 for each oocyte), half of which were then ex-
posed to 100 μM ﬂuvastatin for 16 h. After the 16 h period, currents in-
creased for both groups due to increased surface expression of channels
resulting in current ratios rCtrl = ICtrl / I0= (1.8± 0.1 SE) for the control
group and rFluva = IFluva / I0 = (1.7 ± 0.3 SE) for the ﬂuvastatin treated
group. The current increase was very similar for both groups as shown
in Fig. 6 which displays the ratio rFluva / rCtrl = (0.96 ± 0.2 SE). To eval-
uate the effect of cyclodextrin, oocytes expressing CLC-Ka currents were
measured in standard solution before and after incubation in 1 mM
methyl-beta-cyclodextrin (90min; rcyclodex / rCTRL= 1.1± 0.05, n=7).
Formammalian cell expression the constructswere subcloned in the
pcDNA3 or pRc/CMV vector. HEK293 cells were transfected with plas-
mid DNA encoding CLC-Ka and human Y98A barttin in a 1:1 weight
ratio using a Ca2+ phosphate precipitation method or the Effectene re-
agent (Qiagen). For the identiﬁcation of transfected HEK293 cells, a
plasmid encoding the CD8 antigen or, alternatively, a plasmid encoding
GFP was co-transfected. The transfected cells were identiﬁed by
microbeads coated with anti-CD8 antibodies (Dynabeads M-450 CD8;
Dynal, Great Neck, NY) or by their ﬂuorescence emission. Electrophysi-
ological experiments were performed typically 1–3 days after transient
transfection. Whole-cell patch-clamp recordings were performed using
an Axopatch 200B ampliﬁer (Molecular Devices, Sunnyvale, CA) or an
EPC-7 (List, Darmstadt) as previously described [10,12,17]. Pipettes
were pulled from borosilicate glass (Harvard Apparatus, Holliston,
MA) and had resistances of 2.2 to 3.2 MΩ. The series resistance wascompensated 60 to 80% by an analog procedure, such that the estimated
voltage error as a result of access resistance was alwaysb2 mV. The ex-
tracellular solution contained (in mM): 140 NaCl, 4 KCl, 2 CaCl2, 1
MgCl2, and 5 HEPES, whereas the pipette solution contained 120 NaCl,
2 MgCl2, 5 EGTA, and 10 HEPES. Both solutions were adjusted to pH
7.4 with NaOH. For the experiments on MDCK cells and experiments
concerning the Ca2+ and pH effect, the extracellular standard solution
contained (in mM): 145 NaCl, 2 CaCl2, 2 MgCl2, and 10 HEPES (pH
7.3) (osmolarity, 271 mOsm). To study Ca2+ dependence of CLC-Ks
the concentration of CaCl2 in the extracellular solution was varied be-
tween 0.1 and 30 mM, adjusting the osmolarity by mannitol and keep-
ing the chloride concentration constant. HEPES was replaced by MES
buffer in solutions at pH b 7. The intracellular solution contained (in
mM): 130 CsCl, 2 EGTA, 2 MgCl2, and 10 HEPES (pH 7.3) (osmolarity
233 mOsm). MDCK cells developed rather large endogenous currents
1 day after splitting. However, at day 1 after transfection and few
hours after splitting endogenous currents were negligible and allowed
recordings of heterologously expressed CLC-Ka/barttin channels. Patch
recordings inHEK293 cellswere obtained by voltage pulses fromahold-
ing potential of 0 mV to various test potentials, from−120 to+100mV
for 400ms. Pulses endedwith a tail pulse to−80mV. ForMDCK record-
ings (Fig. 3C), after a prepulse to 60mV for 100ms, channels were stim-
ulated with potentials ranging from−140 to 80 mV with 20 mV
increments for 1000 ms. Pulses ended with a tail pulse to 80 mV for
200 ms. For CLC-K1 recording (Fig. 5), after a prepulse to 65 mV for
200 ms, channels were stimulated with potentials ranging from−120
to 100 mV with 10 mV increments for 400 ms. Pulses ended with a
tail pulse to 65 mV. To evaluate niﬂumic acid (Fig. 3A), [Ca2+] and ki-
nases effects (Fig. 6A, E), CLC-Ks were stimulated with repetitive 10
ms pulses to 60 mV delivered once per second. Current traces were ﬁl-
tered at 1 kHzwith a 4-pole low-pass Bessel ﬁlter and acquired at 5 kHz
with the Clampex + Clampﬁt program (Molecular Devices) or with
GePulse (custom).
2.2. Chemical synthesis
RT-93 was synthesized in our laboratory. For the electrophysiologi-
cal recordings, compounds were dissolved in DMSO daily, and diluted
to the ﬁnal concentration in the extracellular solution. DMSO never
exceeded 0.2%, a concentration without effect on CLC-K channels.
2.3. Statistical analysis
Data are shown as mean ± SEM, unless speciﬁed otherwise; n re-
ﬂects the number of cells. The unpaired t test was used to compare
themean values, and P b 0.05 or P b 0.01 was used to indicate statistical
signiﬁcance.
3. Results
3.1. Whole-cell recordings of CLC-K channels
In agreement with previous studies, when expressed in Xenopus oo-
cytes, both CLC-Ka and CLC-Kb channels show time- and voltage-
dependent gating (Fig. 1A, B) [10,13,15,19]. Differently, CLC-Ka and
CLC-Kb channels expressed in HEK293 give rise to currents with a linear
current–voltage relationship (Fig. 1C, D) [17], suggesting that CLC-Ks
may behave as constitutively open channels in this cellular system.
3.2. Pharmacological characterization of CLC-K channels
The different biophysical behavior of CLC-Ks in HEK293 cells com-
pared to that in oocytes prompted us to investigate the pharmacological
properties of these channels in mammalian cells, using known CLC-K
blockers and openers.
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Fig. 1. Benzofuran derivatives inhibit CLC-K channels. Representative current traces of CLC-Ka (upper panel) and CLC-Kb (lower panel) channels before and after the perfusion of 50 μMRT-
93 in Xenopus oocytes (A, B) and HEK293 cells (C, D).
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We have previously demonstrated that the noncoplanar phenyl-
benzofuran carboxylic acid derivatives are the most potent CLC-Ka in-
hibitors described so far in Xenopus oocytes [15]. Speciﬁcally, in a
screening of different derivatives, we observed that the compound RT-
93 (inset in Fig. 2) showed the highest blocking efﬁcacy, with a concen-
tration of 50 μM able to reduce CLC-Ka and CLC-Kb currents by~85% in
Xenopus oocytes (Fig. 1A, B) [15]. When tested in HEK293 cells, the
same RT-93 concentration reduces CLC-Ka and CLC-Kb currents
by~80% and~67%, respectively (Fig. 1C, D). These data indicate that
this compound inhibits human CLC-K channels in both cellular systemsRT-93 MT-189 JBL-44
1
10
100
IC
50
 (μ
M
)
RT-93 MT-189 JBL-44
Fig. 2. Effect of benzofuran derivatives on CLC-Ka. The mean values of the IC50 measured
at+60 mV for RT-93, MT-189 and JBL-44. The chemical structures of the tested com-
pounds are shown in the upper panel. Data are mean ± SE of n= 6–12 cells.with a similar afﬁnity (CLC-Ka: IC50 = 7.0 ± 0.9 μM in oocytes and
IC50 = 11.3 ± 2.3 μM in HEK293 cells; CLC-Kb: IC50 = 6.0 ± 0.9 μM
in oocytes and IC50 = 15.1 ± 3.6 μM in HEK293 cells). The efﬁcacy of
benzofuran blockers and the conclusion that a blocking binding site is
present in HEK cells are further supported by the observation that
other potent benzofuran derivatives, such as MT-189 and JBL-44, are
also able to inhibit CLC-Ka and CLC-Kb currents to the same extent as
the inhibition observed in oocytes [15] (Fig. 2).
3.2.2. Activating binding site
CLC-Ka in Xenopus oocytes is greatly potentiated by [NFA] b1 mM
but it is blocked by [NFA] ≥1 mM [14,15], thus displaying a biphasic
pharmacological response. This suggests that the mechanism of action
of NFA is complex [16] and probably involves the binding to two differ-
ent binding sites, with opposite effcects [19]. Surprisingly, in HEK293
cells, the application of 300 μM NFA blocks CLC-Ka by~70% (Fig. 3A).
Current inhibition is observed at all tested concentrations in the range
between 0.3 μM and 1 mM with an estimated IC50 of~200 μM
(Fig. 3B). In Fig. 3B we illustrate the biphasic response to NFA of CLC-
Ka in Xenopus oocytes, superimposed with the pure blocking effect in
HEK293 cells. We next tested if we could recover NFA-mediated activa-
tion of CLC-Ka in a renal epithelial cell line, MDCK cells. However, as in
HEK293, also in MDCK cells, CLC-Ka currents exhibit a linear current–
voltage relationship (Fig. 3C) and are blocked by NFA with an apparent
IC50 of~200 μM (Fig. 3C, D).
In oocytes, the activating effect of NFA was even more pronounced
for CLC-Kb. Indeed, NFA potentiated CLC-Kb even at concentrations
higher than 1 mM [14]. In contrast, in HEK293 cells, CLC-Kb is always
inhibited with an apparent IC50 of~300 μM (Fig. 4).
3.3. Insight into the expression system-dependent activity and pharmacology
of CLC-K channels
The distinct biophysical and pharmacological proﬁle of human CLC-
Ks expressed in HEK293 cells and Xenopus oocytes might be inﬂuenced
by a different channel modulation by extracellular and intracellular
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Fig. 3. NFA does not activate CLC-Ka expressed in HEK293 and MDCK cells. (A) CLC-Ka
whole-cell patch-clamp traces before and after the perfusion of 300 μM NFA in HEK293
cells. (B) Comparison of the dose–response relationship of NFA (in the inset) for CLC-Ka
channels expressed in oocytes (empty circles) and HEK293 cells (ﬁlled circles), measured
at +60 mV. Data are mean ± SE of n= 10–15 cells. (C) Typical current traces of CLC-Ka
expressed in MDCK cells in control solution (upper panel) and effect of 200 μM NFA on
CLC-Ka in MDCK cells (bottom panel). The mean current was plotted as function of time.
Different colors and symbols correspond to the solutions applied during the experiment
(CTRL: control; NFA: niﬂumic acid; NaI: blocking solution) as indicated by the bar on
top of the ﬁgure. (D) Comparison of the effect of 200 μM NFA on CLC-Ka expressed in
HEK293 (n= 5) and MDCK cells (n= 4). Steady-state currents measured in NFA were
normalized to those measured in the absence of NFA. Error bars indicate SD.
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NFA inhibition of CLC-Kb channels expressed in HEK293 cells, monitored at +60 mV. Dif-
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and by the lipid membrane composition.C
NFA 300µM 
0
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CLCK1/
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CLCK1
I N
FA
/I 0
Fig. 5. Barttin does not affect CLC-K1 inhibition by NFA. Representative whole-cell patch-
clamp traces of CLC-K1 channels expressed with (A) and without (B) barttin in HEK293
cells, before and after the application of 300 μMNFA. (C) Bar graph of 300 μMNFA inhibi-
tion of CLC-K1 channels expressed in HEK293 cells, with and without barttin. Data are
mean ± SE of n= 6 cells.3.3.1. Role of barttin in NFA-mediated effect
Therefore, we ﬁrst tested whether the distinct pharmacological
properties of CLC-K channels expressed in HEK293 cells may be due to
a different interaction with the accessory barttin subunit, whose role
in modulating channel gating is not yet well understood [10,21]. Inter-
estingly, CLC-K1 is the only CLC-K channel giving rise to detectable cur-
rents even in the absence of barttin [10,21], and, differently fromCLC-Ka
and CLC-Kb, CLC-K1 is always inhibited by NFA in Xenopus oocytes [22].
Therefore, we expressed CLC-K1 channels in HEK293 cells alone or co-
transfected with barttin. In agreement with previous studies [22],
NFA inhibits CLC-K1/barttin channels at all tested concentrations
(Fig. 5A). The application of 300 μM NFA to cells expressing CLC-K1
without barttin still induces a block with a similar potency (Fig. 5B, C).
These results suggest that barttin does not modulate NFA block at
least on CLC-K1.
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We next explored whether a different modulation by extracellular
Ca2+, pH and protein kinases could contribute to the different behavior
of CLC-K channels in oocytes andmammalian cell lines. Human, rat, and
mouse CLC-K channels are activated by extracellular Ca2+ when
expressed in Xenopus oocytes [10,11,23]. Recently, the Ca2+ binding
site was identiﬁed through an extensive mutagenic screen and homolo-
gymodeling of CLC-Ka, [23,24]. Surprisingly, CLC-Ka currents in HEK293
cells show only a slight (although signiﬁcant) Ca2+-dependence. At
0.5 mM Ca2+, CLC-Ka currents are~80% of the currents recorded at
30 mM Ca2+ (Fig. 6A, C). Interestingly, CLC-Kb currents exhibit a more
marked Ca2+ sensitivity resembling that found in oocytes. Indeed, at
0.5 mM Ca2+, CLC-Kb currents are~50% of the maximum current level
at 30 mM (Fig. 6B, C). Therefore we can conclude that CLC-K channels
are Ca2+ sensitive regardless of the expression system, even though
this sensitivity is reduced in HEK293 cells compared to oocytes.
CLC-K channels have a biphasic extracellular pH dependence being
strongly inhibited by acidic as well as by alkaline pH in Xenopus oocytes
[23,25]. Here we establish that inhibition by acidic pH is a feature
retained by CLC-K channels expressed in HEK293 cells, even if slightly
less evident compared to Xenopus oocytes. Indeed, CLC-Ka currents at
pH 6.2 are~56% of those recorded at pH 7.3 and further decrease at
pH 5.5 (~11%) (Fig. 6D–F).
CLC-Ks are modulated by protein kinases [7,8,13]. Paulais et al. re-
ported a cAMP-dependent modulation of CLC-K1 in the mouse cortical
thick ascending limb [7]. In order to test whether such a regulation isp
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cAMP on CLC-Ka channels expressed in HEK293 cells using two different
approaches. First, we recorded CLC-Ka currentswith andwithout 500 μM
cAMPadded to the pipette solution. Differently fromdata on endogenous
mCLC-K1 [7], we do not observe any current activation by cAMP in this
experimental condition (n = 10 cells each; Fig. 7A). In a second ap-
proach, we acutely perfused CLC-Ka expressing cells with themembrane
permeable cAMP analog DB-cAMP. In this case, we observe no statistical-
ly signiﬁcant current potentiation (n= 6 cells, Fig. 7B).
Based on the results by Lourdel et al. on mCLC-K2 in mouse distal
convoluted tubule [8], we next tested the potential role of protein ki-
nase C (PKC) on CLC-Kb currents in HEK293 cells. The perfusion of
whole-cell CLC-Kb patches with the PKC activator 4β-PDB (500 nM) in-
duces an ~35% inhibition of the currents (n=4 cells, Fig.7C,D). The cur-
rent reduction induced by 4β-PDB is not observed when 1 μM
chelerythrine, a PKC inhibitor, is included in the patch pipette (n = 4
cells, Fig.7C,D). Thus, CLC-Kb in HEK293 cells responds to PKC activation
similarly to CLC-K2 in mouse kidney tubules.
3.3.3. Role of membrane cholesterol
The different gating and pharmacological properties shown by CLC-
Ks when expressed in oocytes and HEK293 cells may arise from differ-
ent protein–lipid hydrophobic interaction in the membrane of
HEK293 cells compared with that in oocytes, as shown for other chan-
nels [26]. Therefore, we examined the effects of the reduction in mem-
brane cholesterol on CLC-K channel activity, by treating both oocytesH
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the presence of the PKC inhibitor, chelerythrine, in the patch pipette, 4β-PDB induces almost
no inhibition (n= 4 each, P b 0.05). Data are mean ± SE.
2489P. Imbrici et al. / Biochimica et Biophysica Acta 1838 (2014) 2484–2491and HEK293 cells with methyl-beta-cyclodextrin or ﬂuvastatin. Cyclo-
dextrin lodges the hydrophobic cholesterol molecule inside its ring,
thus reducing its concentration and increasingmembrane ﬂuidity. Incu-
bation of either oocytes or HEK293 cells expressing CLC-Ka in 1 mM
methyl-beta-cyclodextrin does not alter signiﬁcantly the functional ex-
pression level of the channel (Fig. 8A, B). Fluvastatin, instead, lowersA B
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Fig. 8.Reducingmembrane cholesterol content does not alter CLC-K functional expression.
(A) Bar graph showing CLC-Ka current variation at +60 mV in Xenopus oocytes after
90 min incubation with methyl-beta-cyclodextrin 1 mM or after incubation with
100 μM ﬂuvastatin. Data are mean ± SE. (B) Bar graph showing lack of effect of 1 mM
methyl-beta-cyclodextrin and 100 μM ﬂuvastatin on CLC-K currents expressed in
HEK293 cells. CLC-K currents recorded after incubation with 1 mM methyl-beta-
cyclodextrin (Icyclodex / ICTRL = 1.18 ± 0.2, n= 11) or after 12 h incubation with 100 μM
ﬂuvastatin (IFLUVA / ICTRL = 1.1 ± 0.2, n= 8–15) were normalized to those acquired in
control solution at +60 mV, in HEK293 cells. Data are mean ± SE.cholesterol synthesis by inhibiting theHMG-CoA reductase [27].We ob-
serve that incubation with ﬂuvastatin (100 μM) for 16 h does not affect
CLC-Ka current magnitude in Xenopus oocytes (Fig. 8A). Similarly, the
incubation with 100 μM ﬂuvastatin at the time of CLC-Kb transfection
or 12 h after transfection does not signiﬁcantly affect CLC-Kb current
amplitude inHEK293 cells (Fig. 8B). These results rule out thepossibility
that an increase in membrane ﬂuidity, due to a reduction of membrane
cholesterol, affects CLC-K channel expression and folding.
4. Discussion
Here we show that CLC-Ka and CLC-Kb channels exhibit different
pharmacological properties, in addition to a different biophysical behav-
ior [10,13,15,17,19], when they are expressed in frog cells or in human
cell lines. Indeed, in Xenopus oocytes, both CLC-Ka and CLC-Kb display
time and voltage dependent gating. Conversely, in HEK293 cells, CLC-
K currents lack the characteristic time and voltage dependent compo-
nents. In addition, in Xenopus oocytes, a blocking site and an activating
binding site have been identiﬁed [14,15,19]. In contrast, in HEK293
cells we could only detect the inhibitory activity.
In fact, the analysis of known CLC-K blockers, such as the benzofuran
derivatives RT-93 andMT-189, reveals that these compounds are potent
inhibitors of human CLC-Ks also in mammalian cell lines, and their
channel afﬁnity is similar even though slightly lower than that mea-
sured in Xenopus oocytes. This result conﬁrms that the blocking binding
site is active and it is exposed to high afﬁnity ligands that act from the
extracellular side of themembrane inmammalian cells as well as in oo-
cytes. On the other hand, the different efﬁcacy suggests that the activity
of CLC-K channels is different in the two biological systems.
Surprisingly, this study further reveals that the NFA-mediated cur-
rent potentiation found in CLC-Ks expressed in oocytes [14] is not
seen in HEK293 and MDCK cells, where NFA blocked CLC-Ka and CLC-
Kb at all tested concentrations. One hypothesis to explain the different
response to NFA may be that the activating binding site is masked and
less easily accessible when human CLC-Ks are expressed in HEK293
cells. Alternatively, and more likely, we could envisage that the open
probability of CLC-K channels in HEK293 cells is near maximal [21],
such that, even when NFA binds to the activating site, it cannot further
activate the channel. Conversely, in oocytes, the low probability of
CLC-K channels (≪0.5) [19,23,25] would allow a dramatic current
increase.
Actually, CLC-K openers as NFA would be highly desirable to treat
conditionswhere a reduced channel function is observed, as in recessive
Bartter syndrome. In this scenario, we cannot rule out that NFA would
still be capable of activating CLC-Kb mutant channels with a reduced
open probability, thus restoring the large open probability displayed
bywild-type channelswhen expressed inmammalian cell lines. Further
studies with site-directed mutants and/or other compounds are re-
quired to unmask the presence of the activating site.
The different channel folding and/or modulation by cellular factors
may at least in part account for the different biophysical and pharmaco-
logical properties of CLC-Ks in mammalian cell lines and Xenopus oo-
cytes. First we investigated whether the regulation by extracellular
factors such as Ca2+ and pH could be altered and contribute to the re-
ported differences. Indeed, CLC-K channels expressed in Xenopus oo-
cytes and endogenous CLC-K channels are highly sensitive to
extracellular Ca2+ [8–10,23,25]. Interestingly, Ca2+ regulation is found
only in CLC-Ks among CLC proteins suggesting that this is an important
feature of these channels. Furthermore, some CLC-Kbmutants associat-
ed to Bartter syndrome present altered Ca2+ and pH sensitivity when
expressed in Xenopus oocytes [28]. In our experiments, CLC-Ka channels
expressed in HEK293 cells are much less sensitive to extracellular Ca2+.
Interestingly, the reduced Ca2+ sensitivity displayed by CLC-Ka in
HEK293 cells parallels the lack of NFA potentiation, thus supporting
the reciprocal modulation of CLC-Ka observed in oocytes for Ca2+ and
NFA [14]. The differences in Ca2+ sensitivity might again be related to
2490 P. Imbrici et al. / Biochimica et Biophysica Acta 1838 (2014) 2484–2491the different open probability of the channels in Xenopus oocytes and
HEK293 cells. CLC-Kb channels instead retain a signiﬁcant Ca2+ sensi-
tivity. Although the physiological importance of the Ca2+-dependence
of renal chloride channels is unclear, these results support the idea
that an increased external [Ca2+] could stimulate NaCl absorption by
the thick ascending limb, where CLC-Kb is located, and thus Ca2+ reab-
sorption. The analysis of the pH sensitivity conﬁrms that CLC-Ka chan-
nels expressed in HEK293 cells are modulated by a change in
extracellular pH, even if slightly less pronounced than those in oocytes.
In addition, speciﬁc post-translational modiﬁcations, like phosphor-
ylation [7,8,13,29], glycosylation [17], cysteine oxidation [30], or nucle-
otide binding [30], that are cell-type dependent and likely differ in
Xenopus oocytes and mammalian cell lines, may account for the ob-
served differences in CLC-K channels. Our results on CLC-Ka and CLC-
Kb channel phosphorylation show that CLC-Kb currents in HEK293
cells respond to PKC activation similarly to CLC-K2 in mouse kidney tu-
bules [8] while CLC-Ka seems not to be activated by cAMP as CLC-K1 in
mouse kidney tubules [7]. This suggests that CLC-K regulation is com-
plex and may differ in different species. These initial experiments pro-
vide a promising starting point for a deeper investigation of the
regulation of CLC-K channels by intracellular pathways.
Accessory subunits are known to inﬂuence the biophysics and phar-
macology of ion channels. Therefore we also attempted to determine
whether the regulatory barttin subunit could affect the pharmacology
of CLC-Ks [10,21]. As CLC-K1 is the only CLC-K channel thatmediates cur-
rents also in the absence of barttin we chose this channel isoform to test
the contribution of barttin to the effect of NFA. Our results show that
barttin does not affect neither CLC-K1 gating nor inhibition by NFA. Nev-
ertheless, as the structural requirements for CLC-K/barttin interaction are
still unclear [31,32], we can still expect that different CLC-K channel-
barttin contacts occur in HEK293 cells and Xenopus oocytes, thus affect-
ing CLC-Ka and CLC-Kb gating, NFA, and Ca2+ modulation. Another pos-
sibility explaining the different functional properties is that CLC-Ka and
CLC-Kb channels assemblewith unidentiﬁed endogenous accessory sub-
units in HEK293 cells, as reported for other channels [33,34].
Furthermore, lipid–protein interactions that strictly depend on the
speciﬁc membrane environment are known to impact channel func-
tions [26]. Our investigation of the role of membrane cholesterol rules
out its involvement in CLC-Ks expression and gating in oocytes and
mammalian cells.
In conclusion, our results emphasize the importance of the cellular
expression environment in the efforts to correlate the biophysical and
pharmacological proﬁle of heterologously expressed CLC-K channels
with that of endogenous human Cl− currents. In this context, we con-
clude that HEK293 cells represent a valid biological system to screen
CLC-K high afﬁnity blockers and to drive rational drug development
for a translational medicine. Future experiments are required to ascer-
tain the possibility to activate CLC-K channels in mammalian cells and
the structural requirements for activating compounds.
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